Parameter
| Biomarker | FIB-4 | Full name | Fibrosis-4 Index | Molecular Type | Scoring measures (based on age, AST, ALT, platelet count) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Assessment OF LIVER FIBROSIS | ||
| Disease | Metabolic Associated Fatty Liver Disease (MASLD) | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Serum (combined with age and platelet count should be considered | ||
| Pathobiological Mechanisms | It was calculated by the formula (FIB-4 = age ×AST/(platelet count ×√ALT)). Age reflects the cumulative effect of liver disease; AST/ALT ratio reflects the degree of liver cell injury. Platelet count is associated with portal hypertension and fibrosis (thrombocytopenia in fibrosis). FIB-4 can quickly assess the risk of fibrosis in patients with MASLD by simple clinical parameters | ||||
| Clinical Availability Status | Non-invasive fibrosis screening markers are widely used in clinical practice and recommended by many guidelines for initial fibrosis stratification of MASLD, such as screening high-risk patients who need further liver biopsy or LSM testing | ||||
| Notes and Dynamics | FIB-4 is simple to calculate and has a high negative predictive value (>90%) for advanced fibrosis, which can effectively exclude low-risk patients. However, its accuracy decreases in middle-aged people (40-65 years old) and patients complicated with thrombocytopenia (such as other hematological diseases), so it needs to be | ||||